AKAN
AKAN
NASDAQ · Pharmaceuticals

Akanda Corp

$0.84
-0.01 (-1.40%)
As of Nov 7, 2:59 AM ET ·
Financial Highlights (FY 2026)
Revenue
9.86M
Net Income
-1,743,661,586
Gross Margin
-60.4%
Profit Margin
-17,689.8%
Rev Growth
-53.8%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -60.4% -60.4% 35.1% 35.1%
Operating Margin -18,688.2% -16,819.4% 19.5% 18.5%
Profit Margin -17,689.8% -16,805.4% 13.3% 12.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 9.86M 21.34M 707.3K 858.5K
Gross Profit -5,958,394 -12,902,542 247.9K 300.9K
Operating Income -1,842,047,760 -3,589,958,822 138.2K 159.0K
Net Income -1,743,661,586 -3,398,214,437 94.3K 103.5K
Gross Margin -60.4% -60.4% 35.1% 35.1%
Operating Margin -18,688.2% -16,819.4% 19.5% 18.5%
Profit Margin -17,689.8% -16,805.4% 13.3% 12.1%
Rev Growth -53.8% -53.8% +7.8% +11.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 84.3K 84.3K 606.2K 721.3K
Total Equity 1.02M 1.02M 1.23M 1.39M
D/E Ratio 0.08 0.08 0.49 0.52
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -1,825,506,034 -3,755,371,875 212.4K 232.8K
Free Cash Flow — — 76.9K 86.9K